Metabolon, Inc. is the world leader in the field of metabolomics, developing and patenting the industry’s leading biochemical biomarker discovery and profiling platform. Metabolytics, its biomarker discovery and analysis business, is used by pharmaceutical, biotechnology, food and agricultural companies and clinical researchers to quickly identify and measure the biochemicals in a biological sample through its proprietary global processing method. Metabolon also has a broad pipeline of laboratory developed tests in obesity-related conditions and cancer, including Quantose IRTM for insulin resistance and Quantose IGTTM for impaired glucose tolerance.
David Pierson serves as a director on the Board of Metabolon.
Visit: www.metabolon.com